Comments on: Fangda Advises Huaota Biopharmaceutical on Global Collaboration and Licensing Agreement with Almirall for a Novel Monoclonal Antibody in Medical Dermatology

Comments on: Fangda Advises Huaota Biopharmaceutical on Global Collaboration and Licensing Agreement with Almirall for a Novel Monoclonal Antibody in Medical Dermatology /press-release/fangda-huaota-almirall/ Thu, 16 Apr 2026 09:33:30 +0000 hourly 1